Clinical Trial

A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 15, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-25; most recent amendment 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-01-27
Trial Details
NCT Number NCT06706752
Lead Sponsor Sutter Health
Conditions Cancer
Enrollment 30 participants
Start Date 2025-01-24
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-15